TG Therapeutics TGTX
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 88th percentile, 5-year average 7.4x
#2808 of 2994 stocks by PE (1 = cheapest)
Around its usual level · 57th percentile, 5-year average 22.9x
#5106 of 5331 stocks by PB (1 = cheapest)
Below its usual level · 31st percentile, 5-year average 133.5x
#4527 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 17.04 | – | 22.95 | 57% (pricier than usual) | #5106 of 5331 (1 = cheapest) |
| PE | 96.28 | 24.21 | 7.41 | 88% (pricier than usual) | #2808 of 2994 (1 = cheapest) |
| PS | 10.86 | 7.82 | 133.47 | 31% (cheaper than usual) | #4527 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on TGTX.
Sign in to join the discussion.